生产企业：Bristol-Myers Squibb
Idecabtagene vicleucel is an autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
Idecabtagene vicleucel is an autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain. The single chain variable fragment (scFv) allows for B-cell maturation antigen specificity of the CAR. The CD23ζ cytoplasmic domain mediates T-cell activation by CD2, a T-cell surface adhesion molecule. 4-1BB enhances cytotoxic T-cell activity as well as the production of interferon-γ. Idecabtagene vicleucel binds to B-cell maturation antigen expressing cells. Binding to the target leads to proliferation of idecabtagene vicleucel, secretion of cytokines, and lysis of the targeted cells.
Idecabtagene vicleucel is indicated to treat adult patients with relapsed or refractory multiple myeloma who have tried at least 4 other lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 monoclonal antibody.
共 2 项相关疾病
